⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20817251 | 1.00 | — | — | |
| SCHEMBL5320674 | 0.78 | — | — | |
| SCHEMBL4957102 | 0.78 | — | — | |
| SCHEMBL8535 | 0.78 | — | — | |
| SCHEMBL8703894 | 0.78 | — | — | |
| SCHEMBL25383149 | 0.76 | — | — | |
| SCHEMBL9073103 | 0.76 | — | — | |
| SCHEMBL25383152 | 0.76 | — | — | |
| SCHEMBL887143 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL25381571 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167109-A1 | Aminopiperidine Amides, Derivatives, Compositions, and Uses Related to CXCR4 Modulation | UNIV EMORY (US) | 2023-06-01 | — | — | US | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20230167109-A1 | Aminopiperidine Amides, Derivatives, Compositions, and Uses Related to CXCR4 Modulation | UNIV EMORY (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2021217143-A1 | AMINOPIPERIDINE AMIDES, DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 MODULATION | EMORY UNIVERSITY (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | disclosed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | disclosed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-6960574-B2 | Antagonists of RF-amide neuropeptides | UNIVERSITY OF FLORIDA (US) | 2005-11-01 | — | — | US | disclosed |
| US-6797707-B2 | THERAPEUTIC TREATMENT OF OPIATE AND NICOTINE ADDICTION, DRUG DEPENDENCE, AND TOLERANCE; A POLYPEPTIDE DERIVATIVES HAVING N-TERMINAL 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONYL GROUP, C-TERMINAL ARGININE- AMIDE GROUP | UNIVERSITY OF FLORIDA | 2004-09-28 | — | — | US | disclosed |
| US-20040176340-A1 | Antagonists of RF-amide neuropeptides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-09-09 | — | — | US | disclosed |
| WO-2003084303-A2 | ANTAGONISTS OF RF-AMIDE NEUROPEPTIDES | UNIVERSITY OF FLORIDA (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2000055156-A1 | SUBSTITUTED AROMATIC AMIDINE DERIVATIVE AND MEDICINAL COMPOSITION COMPRISING THE SAME | C & C RESEARCH LABORATORIES (KR) | 2000-09-21 | — | — | WO | disclosed |